Preoperative Breast Irradiation
Launched by THE NETHERLANDS CANCER INSTITUTE · Oct 20, 2016
Trial Information
Current as of May 12, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Histologically proven invasive breast carcinoma
- • cT1-2N0 breast cancer
- • cM0
- • female patients ≤ 50 years
- • planned breast conserving surgery
- • ability to undergo irradiation and surgery
- • signed written informed consent
- Exclusion Criteria:
- • prior surgery or radiotherapy for the protocol tumor (neoadjuvant chemotherapy or endocrine therapy is allowed)
- • planned oncoplastic reduction mammoplasty
- • cTis
- • extensive calcifications on mammagram (Birads 3,4 or 5)
- • cT3-4 and/or cN1-3 invasive carcinoma
- • distant metastasis
About The Netherlands Cancer Institute
The Netherlands Cancer Institute (NKI) is a leading research and treatment center dedicated to advancing the understanding and management of cancer. Renowned for its cutting-edge research, NKI fosters innovation in oncology through a multidisciplinary approach that integrates laboratory research, clinical trials, and patient care. With a commitment to translating scientific discoveries into effective therapies, the institute collaborates with national and international partners to enhance cancer treatment outcomes. NKI's state-of-the-art facilities and expertise in various cancer types position it as a pivotal contributor to the global fight against cancer, aiming to improve survival rates and quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Patients applied
Trial Officials
Astrid Scholten, MD, PhD
Principal Investigator
Antoni van Leeuwenhoek
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials